Patents Examined by F. T. Moezie
  • Process for synthesizing peptides - fragment condensation
    Patent number: 5322931
    Abstract: A solution phase process for making peptides having biological activity or peptide intermediates which can be used to prepare peptides having biological activity is described. The process involves the condensation reaction of two peptide fragments.
    Type: Grant
    Filed: October 22, 1992
    Date of Patent: June 21, 1994
    Assignee: Eastman Kodak Company
    Inventors: John C. Hubbs, Stephen W. Parker
  • Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
    Patent number: 5317010
    Abstract: Analogues of bovine and human parathyroid hormone, wherein twenty-fifth, twenty-six and twenty-seventh positions of the natural hormone, Arg-Lys-Lys- each have been substituted with Ala, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val have been found to retain bone cell effect with minimal effects on blood pressure and smooth muscle, including cardiac muscle. It has further been found that this effect can be obtained by using a synthetic PTH containing only the first 34 amino acids of PTH, with substitution at the twenty-fifth, twenty-sixth and twenty-seventh amino acids as described. These analogues of PTH also are effective in the treatment of osteoporosis and other bone diseases.
    Type: Grant
    Filed: October 10, 1991
    Date of Patent: May 31, 1994
    Assignee: Peter K. T. Pang
    Inventors: Peter K. T. Pang, Jie Shan
  • Glucan sulfate, stabilized fibroblast growth factor composition
    Patent number: 5314872
    Abstract: Fibroblast growth factor (FGF) or a mutein of FGF is stabilized by bringing FGF or a mutein of FGF into contact with a glucan sulfate in an aqueous medium. Thus obtained composition comprising (a) FGF or a mutein of FGF and (b) a glucan sulfate is stabilized, so that it can be advantageously administered to warm-blooded animals.
    Type: Grant
    Filed: June 2, 1989
    Date of Patent: May 24, 1994
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Koichi Kato, Kenji Kawahara, Tomoko Kajio
  • Method for treating corneal endothelial wounds
    Patent number: 5310728
    Abstract: A method for treating corneal endothelial wounds comprises administering TGF-.alpha. to the region of the wound in an amount sufficient to promote the healing of endothelial cells.TGF-.alpha. advantageously is administered into the anterior chamber during ophthalmic surgical procedures, such as during intra-ocular lens implantation. The TGF-.alpha. preferably is administered as an active ingredient in an ophthalmological viscoelastic composition which improves the residence time of the growth factor in the anterior chamber.
    Type: Grant
    Filed: July 23, 1992
    Date of Patent: May 10, 1994
    Assignee: Chiron Ophthalmics, Inc.
    Inventors: Robert W. Shimizu, Gregory S. Schultz
  • Somatotropins with alterations in the .alpha.-helix 3 region
    Patent number: 5310882
    Abstract: The present invention relates to somatotropin analogues with amino acid changes in the .alpha.-helix 3 regions of said somatotropins, changes in the .alpha.-helix 2 regions, combinations thereof plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release, formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptides also are provided.
    Type: Grant
    Filed: November 30, 1990
    Date of Patent: May 10, 1994
    Assignee: American Cyanamid Company
    Inventor: Deborah T. Chaleff
  • Trifluoromethylketone derivatives, processes for preparation thereof and use thereof
    Patent number: 5296591
    Abstract: The trifluoromethylketone derivatives (I) and pharmaceutically acceptable salts thereof have a human leukocyte elastase inhibiting activity and are useful as human leukocyte elastase inhibitors for treating or preventing degenerative diseases. The trifluoromethylketone derivatives (I) have the following formula: ##STR1## wherein R.sup.1 is C.sub.1-6 alkyl which has one or two substituents selected from carboxy, esterified carboxy and di-C.sub.1-6 alkylcarbamoyl; phenyl(C.sub.1-6) alkyl, the phenyl moiety of which may have halogen or nitro or amino substituents and the alkyl moiety of which may have carboxy or esterified carboxy substituents; halo-phenyl; morpholino; or morpholino(C.sub.1-6) alkyl,R.sup.2 and R.sup.3 are each C.sub.1-6 alkyl,X is -- or --NH--, andY is ##STR2## and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 12, 1991
    Date of Patent: March 22, 1994
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Keiji Hemmi, Ichiro Shima, Keisuke Imai, Hirokazu Tanaka
  • Method of purifying human epidermal growth factor
    Patent number: 5290920
    Abstract: Human epidermal growth factor is provided in an ultrapure form characterized by the absence of protein contaminants detectable by capillary electrophoresis analysis. A method for obtaining such ultrapure human epidermal growth factor includes fractionation of a human epidermal growth factor preparation by reversed phase high performance liquid chromatography in the presence of a cationic ion-pairing agent.
    Type: Grant
    Filed: April 16, 1992
    Date of Patent: March 1, 1994
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Dennis R. Sindrey, Chandra M. Dwivedi
  • Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
    Patent number: 5288931
    Abstract: A method for refolding insoluble, improperly folded IGF-I is provided, wherein the IGF-I, precipitated from prokaryotic host cells, it concurrently solubilized, unfolded, and refolded into a biologically active conformation in a single buffer. The buffer contains reducing agent and chaotropic agent to solubilize the IGF-I at concentrations sufficiently low to allow solubilization and folding to occur. Also provided is a triple-protease deficient E. coli host suitable for use in the process.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: February 22, 1994
    Assignee: Genentech, Inc.
    Inventors: Judy Y. Chang, Nancy C. McFarland, James R. Swartz
  • Process and composition for oral hygiene
    Patent number: 5275804
    Abstract: A process for enhancing oral hygiene by reducing oral microflora and for inhibiting the formation of dental plaque by applying, to the oral cavity a composition containing (a)0.1 to 40 parts, by weight, of a higher acyl-N-betaine having the structure ##STR1## where R is a higher alkyl group of from 10 to 18 carbon atoms, or mixtures thereof, and (b) 0.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: January 4, 1994
    Assignee: E. B. Michaels Research Associates, Inc.
    Inventor: Edwin B. Michaels
  • O-glycosylated IGF-1
    Patent number: 5273966
    Abstract: The present invention provides an O-Glycosylated Insulin-like Growth Factor 1 (IGF-1) analog of Insulin-like Growth Factor 1, a seventy amino acids single polypeptide chain which displays relatively high homology with proinsulin, essentially free from unglycosylated IGF-1.
    Type: Grant
    Filed: April 22, 1991
    Date of Patent: December 28, 1993
    Assignee: Kabi Pharmacia AB
    Inventors: Anna Sknottner-Lundin, Linda Fryklund, Par Gellerfors
  • Human tachykinins and their precursor
    Patent number: 5268359
    Abstract: A DNA has the nucleotide sequence shown in FIG. 1. The derived amino acid sequence is also shown in FIG. 1. Novel polypeptides have the amino acid sequence corresponding to amino acids 1 to 126, 20 to 56 and 111 to 126 shown in FIG. 1 and may be prepared by culturing a host organism in which the DNA includes the relevant segment of DNA cut from the nucleotide sequence shown in FIG. 1.
    Type: Grant
    Filed: December 5, 1988
    Date of Patent: December 7, 1993
    Assignee: Medical Research Council
    Inventors: Anthony J. Harmar, John Pascall, Ann McKeown
  • Hemolymphopoietic growth factors, process for purifying and producing hemolymphopoietic growth factors and pharmaceutical compositions made therefrom
    Patent number: 5264418
    Abstract: This invention relates to hemolymphopoeitic growth factors (HLGF-1) that synergize with CSF-1, IL3 and GM-CSF and have pre-B cell potentiating activity. The invention also relates to a process for purifying such HLGF-1's from murine marrow cells and for producing such HLGF-1s by hosts transformed with recombinant DNA molecules comprising DNA sequences encoding the growth factor, and to methods of treatment and compositions characterized by HLGF-1s. These methods and agents are useful in immunoregulatory and hemopoietic applications and therapies.
    Type: Grant
    Filed: December 3, 1987
    Date of Patent: November 23, 1993
    Assignee: The University of Virginia Alumni Patents Foundation
    Inventors: Peter J. Quesenberry, Ian K. McNiece
  • Fibroblast growth factor antagonists
    Patent number: 5252718
    Abstract: Antagonists to basic fibroblast growth factor, a 146 amino acid residue polypeptide, are produced. These antagonists are generally between 10 and 45 residues in length and are characterized by their ability to interact with the FGF receptor and/or inhibit and therefore modulate endothelial and other cell growth in vitro and also in vivo. These antagonists includes the sequence of bovine basic FGF(106-115), namely Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr or a sequence having equivalent residues substituted therein. These peptides are also antagonistic to acidic FGF and other members of the family of FGF peptides. They are effective to combat FGF-promoted mitosis in melanomas and the like.
    Type: Grant
    Filed: April 27, 1992
    Date of Patent: October 12, 1993
    Assignee: The Salk Institute for Biological Studies
    Inventors: J. Andrew Baird, Nicholas C. Ling
  • Angiogenic factor isolated from live yeast cell derivatives and its use in treating wounds or burns in mammals
    Patent number: 5238925
    Abstract: Disclosed herein is purified isolated angiogenic factor, isolated from Live Yeast Cell Derivative. Also disclosed herein are methods to treat mammals suffering from wounds or burns comprising administering the angiogenic factor and pharmaceutical formulations for use in the methods.
    Type: Grant
    Filed: May 9, 1990
    Date of Patent: August 24, 1993
    Assignee: The State of Oregon Acting by and through The State Board of Higher Education on Behalf of the Oregon Health Sciences University
    Inventor: J. Peter Bentley
  • In vitro method of inhibition of HIV using transforming growth factor-.beta .
    Patent number: 5236905
    Abstract: The use of TGF-.beta. to inhibit HIV infection and/or replication is described. Both mature and precursor forms of TGF-.beta. are efficacious in inhibiting production of HIV. The TGF-.beta. used to inhibit HIV may be obtained from natural sources or may be produced by recombinant DNA or chemical synthetic techniques. TGF-.beta.1 and/or TGF-.beta.2 may be used. Additionally, hybrid TGF-.beta.1/.beta.2 molecules may also be utilized.
    Type: Grant
    Filed: August 25, 1988
    Date of Patent: August 17, 1993
    Assignee: Oncogen
    Inventors: Vera Brankovan, Mario N. Lioubin, Anthony F. Purchio
  • Method of ameliorating herpes simplex virus infections using purified nerve growth factor
    Patent number: 5232695
    Abstract: Methods of treatment are described for use of purified nerve growth factor to ameliorate viral infections in an animal caused by Herpes Simplex Virus Types 1 and 2. Compositions are described for use in the treatment comprising purified nerve growth factor alone or in conjunction with a Herpes Simplex Viral antiviral agent.
    Type: Grant
    Filed: December 6, 1990
    Date of Patent: August 3, 1993
    Assignee: G. D. Searle & Co.
    Inventors: Christine L. Wilcox, Eugene M. Johnson, Jr.
  • Anaphylatoxin-receptor ligands
    Patent number: 5223485
    Abstract: Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L-M-Q-T are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states. Also disclosed are anaphylatoxin receptor ligand compositions and a method for modulating anaphylatoxin activity.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: June 29, 1993
    Assignee: Abbott Laboratories
    Inventors: Megumi Kawai, Yat S. Or, Paul E. Wiedeman, Jay R. Luly, Mikel P. Moyer
  • Formulations for stabilizing fibroblast growth factor
    Patent number: 5217954
    Abstract: Pharmaceutical formulations and a method for their preparation are provided. These formulations provide a stabilized basic fibroblast growth factor (bFGF) which is less susceptible to oxidation or metal-induced aggregation by including an amount of a chelating agent effective to stabilize the bFGF.
    Type: Grant
    Filed: April 4, 1990
    Date of Patent: June 8, 1993
    Assignee: Scios Nova Inc.
    Inventors: Linda Foster, Stewart A. Thompson, S. Joseph Tarnowski
  • Human monocyte growth factor
    Patent number: 5216133
    Abstract: A novel growth factor, human monocyte growth factor, stimulating proliferation and differentiation of human peripheral blood monocyte. The factor is a protein produced from human lung cancer cell line and having M.W. of about 21,000. The activity of the factor is heat-sensitive, trypsin-sensitive, chymotrypsin-sensitive, and destroyed by 2-mercaptoethanol. A purification process of the factor is also provided.
    Type: Grant
    Filed: October 31, 1990
    Date of Patent: June 1, 1993
    Assignee: Japan Antibiotics Research Association
    Inventor: Tetsuro Okabe
  • Growth-inhibitory factor obtained from human brain
    Patent number: 5214031
    Abstract: Disclosed are a growth-inhibitory factor which is a pure protein extracted from human brain and having inhibitory action against neurotrophic activity and a cDNA coding for a protein existing in human brain and the lysate from E. coli transfected with the cDNA having growth-inhibitory action, and also a method of inducing growth-inhibiting activity for treatment of Alzheimer disease by using the protein.
    Type: Grant
    Filed: May 6, 1991
    Date of Patent: May 25, 1993
    Inventor: Yoko Uchida